Henriksson A E, Tagesson C, Uribe A, Uvnäs-Moberg K, Nord C E, Gullberg R, Johansson C
Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden.
Ann Rheum Dis. 1988 Aug;47(8):620-7. doi: 10.1136/ard.47.8.620.
The effects of oral natural prostaglandin E2 (PGE2) on symptoms, disease activity, and gastrointestinal functions in rheumatoid arthritis (RA) were studied in an open pilot trial. Twelve patients, six taking and six not taking non-steroidal anti-inflammatory drugs (NSAIDs), received 1 mg natural PGE2 three times a day for six weeks. The treatment was tolerated well and the only side effect noted was slightly looser stools in three patients. Half of the patients reported subjective improvement and none had aggravation of symptoms. The Ritchie articular index and several biochemical inflammation markers decreased and were significantly reduced at the end of the treatment period. The thickness of the small intestinal mucosa increased during the PGE2 treatment. The intestinal permeability pattern, measured by urinary excretion of polyethylene glycols (PEG 400), differed between the patients taking and not taking NSAIDs. The initially high urinary PEG 400 excretion values in the patients taking NSAIDs decreased and the initially low excretion values in patients not taking NSAIDs increased during the PGE2 treatment. The jejunal contents became sterile in 5/6 patients not taking NSAIDs and remained sterile in 1/6 patients taking NSAIDs at the end of the treatment. The treatment period was associated with a reduction of lactobacilli in patients not treated with NSAIDs. Thus the treatment appeared to decrease disease activity and to improve small intestinal functions in patients with RA, findings that need confirmation in a controlled trial.
在一项开放性试验中，研究了口服天然前列腺素E2（PGE2）对类风湿性关节炎（RA）患者症状、疾病活动度及胃肠功能的影响。12例患者，其中6例服用非甾体抗炎药（NSAIDs），6例未服用，接受每日3次、每次1mg天然PGE2的治疗，为期6周。治疗耐受性良好，仅3例患者出现大便稍稀的副作用。半数患者报告主观症状改善，无患者症状加重。治疗期末，里奇关节指数及多项生化炎症标志物下降且显著降低。PGE2治疗期间小肠黏膜厚度增加。通过聚乙二醇（PEG 400）尿排泄量测定的肠道通透性模式，在服用和未服用NSAIDs的患者之间存在差异。服用NSAIDs患者最初较高的尿PEG 400排泄值下降，未服用NSAIDs患者最初较低的排泄值在PGE2治疗期间升高。治疗期末，6例未服用NSAIDs的患者中有5例空肠内容物无菌，6例服用NSAIDs的患者中有1例空肠内容物保持无菌。治疗期间，未接受NSAIDs治疗的患者乳酸杆菌减少。因此，该治疗似乎可降低RA患者的疾病活动度并改善小肠功能，这些发现需要在对照试验中得到证实。
